EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 379-392

  Velpula, Kiran Kumar ^a   Dasari, Venkata Ramesh ^a   Asuthkar, Swapna ^a   Gorantla, Bharathi ^a   Tsung, Andrew J ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Illinois Neurological Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL FUNCTION; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TUMOR XENOGRAFT; WOUND HEALING;

EID: 84867510549     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12235     Document Type: Article

References (51)

1. Cancer Genome Atlas Research Network Collaborators (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
2. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, and Bigner DD (1998). The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4, 148-158.
3. Abounader R and Laterra J (2005). Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7, 436-451.
4. Benvenuti S and Comoglio PM (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213, 316-325.
5. Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, and Kim H (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 71, 7125-7134.
6. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, et al. (2011). Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 13, 461-471.
7. Gentile A, Trusolino L, and Comoglio PM (2008). The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27, 85-94.
8. Habib AA, Hognason T, Ren J, Stefansson K, and Ratan RR (1998). The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor β receptor. J Biol Chem 273, 6885-6891.
9. Trusolino L and Comoglio PM (2002). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2, 289-300.
10. Yasmeen A, Bismar TA, and Al Moustafa AE (2006). ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas. Future Oncol 2, 765-781.
11. Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H, Wakisaka S, and Koono M (1997). Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31, 436-443.
12. Han CB, Ma JT, Li F, Zhao JZ, Jing W, Zhou Y, and Zou HW (2012). EGFR and KRAS mutations and altered c-Met gene copy numbers in primary nonsmall cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Lett 314, 63-72.
13. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta CA, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, et al. (2010). Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 70, 9391-9401.
14. Lo HW (2010). EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol 3, 37-52.
15. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, and Pan BS (2007). Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67, 2081-2088.
16. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, and Safe S (2011). GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res 9, 195-202.
17. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, and Siegfried JM (2011). Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 17, 4425-4438.
18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
19. Trusolino L, Bertotti A, and Comoglio PM (2010). MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11, 834-848.
20. Mueller KL, Yang ZQ, Haddad R, Ethier SP, and Boerner JL (2010). EGFR/ Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 5, 8.
21. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, et al. (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105, 692-697.
22. Huang PH, Xu AM, and White FM (2009). Oncogenic EGFR signaling networks in glioma. Sci Signal 2, re6.
23. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, and White FM (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104, 12867-12872.
24. Karamouzis MV, Konstantinopoulos PA, and Papavassiliou AG (2009). Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 10, 709-717.
25. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158.
26. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, and Vande Woude GF (1997). Met and hepatocyte growth factor/ scatter factor expression in human gliomas. Cancer Res 57, 5391-5398.
27. Velpula KK, Dasari VR, Tsung AJ, Gondi CS, Klopfenstein JD, Mohanam S, and Rao JS (2011). Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PLoS One 6, e18017.
28. Asuthkar S, Nalla AK, Gondi CS, Dinh DH, Gujrati M, Mohanam S, and Rao JS (2011). Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro Oncol 13, 1059-1073.
29. Velpula KK, Dasari VR, Tsung AJ, Dinh DH, and Rao JS (2011). Transcriptional repression of MAD-MAX complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma. Stem Cells Dev 21, 1779-1793.
30. Kermorgant S and Parker PJ (2008). Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 182, 855-863.
31. Wang Y, Chen L, Bao Z, Li S, You G, Yan W, Shi Z, Liu Y, Yang P, Zhang W, et al. (2011). Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways. Oncol Rep 26, 1173-1180.
32. Mimeault M and Batra SK (2011). Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol 21, 479-500.
33. Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, Klopfenstein JD, Dinh DH, and Rao JS (2010). Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One 5, e10350.
34. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al. (2006). Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12, 5369-5376.
35. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, and Laterra J (2000). Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKTdependent pathways. Cancer Res 60, 4277-4283.
36. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, et al. (1998). Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279, 710-714.
37. Ghosh MK, Sharma P, Harbor PC, Rahaman SO, and Haque SJ (2005). PI3KAKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells. Oncogene 24, 7290-7300.
38. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
39. Demuth T and Berens ME (2004). Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70, 217-228.
40. Hoelzinger DB, Demuth T, and Berens ME (2007). Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99, 1583-1593.
41. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, et al. (2006). Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66, 4742-4749.
42. Rich JN, Rasheed BK, and Yan H (2004). EGFR mutations and sensitivity to gefitinib. N Engl J Med 351, 1260-1261.
43. Toth J, Egervari K, Klekner A, Bognar L, Szanto J, Nemes Z, and Szollosi Z (2009). Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma. Pathol Oncol Res 15, 225-229.
44. Wheeler DL, Dunn EF, and Harari PM (2010). Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493-507.
45. Wu X, Zhou J, Rogers AM, Janne PA, Benedettini E, Loda M, and Hodi FS (2012). c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 22, 123-132.
46. Martinez-Palacian A, del Castillo CG, Herrera B, Fernandez M, Roncero C, Fabregat I, and Sanchez A (2012). EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells. Cell Signal 24, 505-513.
47. Sequist LV, von Pawel PJ, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, et al. (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29, 3307-3315.
48. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, and Siegfried JM (2011). Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 17, 4425-4438.
49. Dulak AM, Gubish CT, Stabile LP, Henry C, and Siegfried JM (2011). HGFindependent potentiation of EGFR action by c-Met. Oncogene 30, 3625-3635.
50. Dasari VR, Velpula KK, Alapati K, Gujrati M, and Tsung AJ (2012). Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PLoS One 7, e31884.
51. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290.